Phase 2 Hepatitis B Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People with a body mass index (a measure of body weight relative to height) between 18.5 and below 35
- People who have had a chronic hepatitis B infection documented for at least 6 months before the screening visit
- People whose hepatitis B virus levels in the blood are currently undetectable or below measurable levels due to antiviral treatment
- People who have been taking a single approved antiviral medication for hepatitis B (from a class called nucleoside or nucleotide analogues) for at least 24 weeks before joining, with no change in dose for at least 4 weeks before joining
- People who are willing and able to use effective contraception during the trial
- People who are willing to sign a consent form agreeing to participate
Who may not be able to join:
- People with a history of liver cirrhosis, liver failure, suspected or confirmed liver cancer, or other liver diseases besides chronic hepatitis B
- People with an autoimmune disease (where the immune system attacks the body)
- People who have had a solid organ transplant or a bone marrow/stem cell transplant
- People with serious heart or brain blood vessel conditions that are unstable or not well controlled
- People diagnosed with any cancer in the 5 years before joining the trial
- People who have had an infection requiring medical treatment in the 2 weeks before joining
- People who have had a major injury or major surgery in the 12 weeks before joining, or who have planned surgery or other treatments during the trial period that investigators believe could affect the results
- People whose blood test results during the screening period showed significant abnormalities
- People whose heart electrical activity test (ECG) showed a specific abnormal reading (called prolonged QTcF) or other results that could pose a safety risk
- People with a history of drug use, alcohol misuse, or substance abuse in the 12 months before joining
- People who have recently taken part in another clinical drug trial
- People who are pregnant or breastfeeding
- People who are allergic to any ingredient in the trial medication
- People who are considered ineligible for other reasons, as determined by the trial investigators
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 0518-82342973
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
PartA：Change in mean log10 serum hepatitis B surface antigen levels from baseline at week 12; PartB：Proportion of subjects whose serum hepatitis B surface antigen (HBsAg) had turned negative at week 48; PartC：Proportion of subjects whose serum hepatitis B surface antigen (HBsAg) had turned negative at week 48; PartD：Proportion of subjects whose serum hepatitis B surface antigen (HBsAg) had turned negative at week 48
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.